Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma

(2010) Dorothy A. White et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Topical Rapamycin

(2010) Anna K. Haemel et al.   ARCHIVES OF DERMATOLOGY

Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis From Other Diseases

(2010) Lisa R. Young et al.   CHEST

Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

(2010) Chelsey Woodrum et al.   Journal of Translational Medicine

Tsc2-Rheb signaling regulates EphA-mediated axon guidance

(2010) Duyu Nie et al.   NATURE NEUROSCIENCE

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

(2010) Darcy A. Krueger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated

(2009) Prasanna Sooriakumaran et al.   BJU INTERNATIONAL

Serum Vascular Endothelial Growth Factor-D Levels in Patients With Lymphangioleiomyomatosis Reflect Lymphatic Involvement

(2009) Connie G. Glasgow et al.   CHEST

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

(2009) Marja Lohela et al.   CURRENT OPINION IN CELL BIOLOGY

Sirolimus and Everolimus Induced Pneumonitis in Adult Renal Allograft Recipients: Experience in a Center

(2009) A. Rodríguez-Moreno et al.   TRANSPLANTATION PROCEEDINGS

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

(2009) Nancy Lee et al.   BMC Pharmacology & Toxicology

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex

(2008) Ling-Hui Zeng et al.   ANNALS OF NEUROLOGY

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis

(2008) G.F.L. Hofbauer et al.   BRITISH JOURNAL OF DERMATOLOGY

Developing a national collaborative study system for rare genetic diseases

(2008) Michael S Watson et al.   GENETICS IN MEDICINE

Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function

(2008) L. Meikle et al.   JOURNAL OF NEUROSCIENCE

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Reversal of learning deficits in a Tsc2 +/− mouse model of tuberous sclerosis

(2008) Dan Ehninger et al.   NATURE MEDICINE

Diagnostic Potential of Serum VEGF-D for Lymphangioleiomyomatosis

(2008) Lisa R. Young et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE